TransMedics Group, Inc.

TransMedics Group, Inc.'s next confirmed earnings release is scheduled for November 4, 2026.

As of June 30, 2026, TransMedics Group, Inc. has 34.63M shares outstanding.

As of June 30, 2026, TransMedics Group, Inc. maintains a current ratio of 6.62, meaning it holds 6.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 167.50, indicating elevated leverage, while an interest coverage ratio of 5.56 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, TransMedics Group, Inc. posted a return on equity (ROE) of 36.28, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 12.88, measuring how efficiently the asset base is converted into earnings. The company generates approximately 683,939.26 in revenue per employee across its workforce of 855.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 5.94 indicates how many times TransMedics Group, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, TransMedics Group, Inc. recorded an income tax benefit of -69.28M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 63.51M, leaving 132.78M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Over the twelve months ended June 30, 2026, TransMedics Group, Inc. generated 585.11M in revenue and converted that into 132.78M in net income, yielding earnings per share of 3.35. EBITDA reached 103.31M, while operating income came in at 71.43M.

As of June 30, 2026, TransMedics Group, Inc. holds 413.73M in cash and equivalents against 759.52M in total debt, resulting in a net debt position of 36.17M. Total book value stands at 453.45M, with working capital of 483.90M providing operational flexibility.

TransMedics Group, Inc. produced 127.73M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -58.55M in capital expenditures, free cash flow totaled 69.18M - equivalent to 2.02 per share.

Over the twelve months ended June 30, 2026, TransMedics Group, Inc. posted a gross margin of 58.69, reflecting its pricing power and cost economics. The operating margin of 12.21 and net profit margin of 22.69 provide insight into operational efficiency.